ABSTRACT

Introduction:- Covishield vaccine (Brand name-COVISHIELDTM) is a recombinant, replication- deficient chimpanzee adenovirus vector encoding the SARS-CoV-2 Spike (S) glycoprotein. Objectives:- The study was conducted to evaluate adverse events that occurred after COVISHIELDTM vaccination. Methods:- A cross?sectional, questionnaire based survey was conducted at K.D. Dental College and Hospital, Mathura to compare adverse effects that occurred after COVISHIELD vaccination. This survey was conducted among 121 participants who were the faculties, students and non-teaching staffs who were 18 years and above and who were vaccinated with COVISHIELD vaccines. A self prepared questionnaire was made that composed of questions regarding demographic details, about comorbidities and about the symptoms that were present after 1st and 2nd doses and the distribution of symptoms as per onset and duration of 1st and 2nd doses respectively. Results: -Among 121 participants, 3 participants had past COVID-19 positive history and 17 participants had comorbidities. Among those who were vaccinated with both 1st and 2nd doses of COVISHIELD vaccine, 96 participants showed symptoms after 1st dose of COVISHIELD vaccine. However, 36 participants had showed symptoms after 2nd dose of COVISHIELD vaccine. Symptoms that occurred after 1st and 2nd dose of vaccination disappeared within 2 days. Conclusion:-The present study showed that there was significant reduction in occurrence of symptoms among participants after 2nd dose of COVISHIELD vaccine as compared to1st dose. Keywords: SARS-CoV-2, COVID-19, comorbidities, covishield vaccine
Publication date: 01/05/2023

https://ijbpas.com/pdf/2023/May/MS_IJBPAS_2023_7159.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2023/12.5.7159